The country’s trajectory has been building for years. A fast-growing middle-income population, rising chronic disease burden, and expanding health infrastructure have created both demand and urgency. What is changing now is the environment in which innovation can move, driving faster approvals, a culture of collaboration, digital infrastructure and a government signaling policy readiness to engage global partners in shaping the next era of medicine.

The economic momentum is significant. The Indian health ecosystem has expanded from roughly $372 billion in 2023 to $638 billion in 2025, making it one of the fastest-growing major health markets in the world. The broader industry is expected to exceed $610 billion by 2026, fueled by rising insurance coverage, expanding hospital infrastructure, and growing demand for chronic disease management. Health growth in India continues at approximately 10–12 percent annually, well above the growth rates typical of mature markets, reflecting both rising access and structural transformation.

BIOAsia 2026 reflects this inflection point. The global gathering in Hyderabad, themed “TechBio Unleashed: AI, Automation & the Biology Revolution,” highlights the (bio)convergence of biology, data, and intelligent systems reshaping health worldwide. Organizers emphasize that the meeting aims to drive health transformation and reinforce India’s position as a leading global life sciences force. For multinational innovators, the message is increasingly clear: India is not only where innovation is deployed; it is also where it is developed. It is where innovation is increasingly defined. India has become a go-to market for multinational enterprises.

Policy Signals and Market Scale: From Opportunity to Strategic Partnership

India’s regulatory and policy environment is evolving in ways that matter deeply to multinational innovators. One pivotal shift came with the country’s decision to allow certain medicines approved in specified developed markets to launch without local clinical trials, a move designed to accelerate patient access while aligning more closely with global regulatory science. This policy shift reflected confidence in international data, a commitment to innovation, and recognition that faster access must remain central to national health strategy.

The scale of India’s pharmaceutical and life sciences market reinforces this transformation. The pharmaceutical sector reached approximately $68 billion in 2025 and is projected to grow to more than $170 billion during the next decade, driven by expanding middle-income demand and strong domestic manufacturing. India already supplies roughly one-fifth of the world’s generic medicines. It produces the majority of global vaccines by volume, positioning the country as a central player in global health supply chains.

As Aman Gupta of SPAG/FINN wrote in Medika Life, “India’s health sector is undergoing a profound transformation, bolstered by government-led reforms and a favorable FDI regime. The allowance of 100% foreign direct investment through automatic routes in health and related sectors has already attracted global giants.” His observation reinforces a central reality for multinational innovators: India’s policy environment is increasingly designed not only to welcome global participation, but to encourage long-term strategic partnership in building the future of healthcare.

Investment trends tell the same story. Health and pharmaceutical private equity and venture investments have reached multi-billion-dollar levels annually. At the same time, India’s contract drug development and manufacturing sector is projected to exceed $22 billion within the next decade. These dynamics position India as a growth market and as a strategic partner across the innovation lifecycle from discovery and clinical development to manufacturing and global distribution.

Shakthi Nagappan, CEO of Telangana Life Sciences Foundation, captured this moment clearly, noting that BIOAsia arrives at a time when technology and biology are redefining healthcare and creating “unprecedented opportunities for innovation, investment, and impact.” The language reflects partnership rather than transaction, a signal that India is moving from market opportunity to strategic collaboration.

Digital Infrastructure, BIOAsia and the Multinational Innovation Imperative

India’s digital transformation may be its most potent catalyst for long-term health innovation. Unlike many mature systems, the country is building a national-scale digital health infrastructure designed to connect patients, providers, and health systems across a population of more than 1.4 billion people, with a rising middle class of 400 million.

The Global Digital Health Market is projected to grow from USD 288.55 billion in 2024 to USD 2,688 billion by 2035, expanding at a CAGR of 22.55% during 2025–2035. This surge is driven by the rapid adoption of AI-powered diagnostics, telemedicine, wearable devices, and data analytics solutions that are revolutionizing patient care and operational efficiency worldwide.

Hundreds of millions of citizens are already using digital health services, including telemedicine, electronic prescriptions, and remote care. The Ayushman Bharat Digital Mission is creating an interoperable national health ecosystem, enabling secure health records, improved care coordination, and population-scale data infrastructure that supports research, real-world evidence, and precision health.

For multinational companies, this digital backbone creates a uniquely strategic environment, enabling large-scale clinical research, faster pharmacovigilance, AI-supported health insights, and rapid deployment of innovation across diverse populations. India’s digital infrastructure is not simply modernizing health delivery. It is enabling national-scale transformation.

BIOAsia sits at the center of this conversation and convergence. The gathering reflects India’s ambition to lead at the intersection of biology, artificial intelligence, and scalable innovation. Leaders from industry, government, and science convene not only to discuss growth but to shape the next phase of global life sciences, where biology, data, and digital systems converge to influence global health.

One conference panel, among the many high-powered sessions, brings together global leaders in advanced therapeutics to explore how next-generation modalities are moving from discovery to scalable care. Panelists across biopharma, translational science, and hospital systems are examining progress in cell and gene therapies, mRNA, and radiopharmaceuticals, underscoring that innovation now depends as much on manufacturable scale and delivery as on scientific breakthrough. India’s expanding capabilities in clinical research and bioprocessing strengthen its role as a key partner in advancing next-generation therapies.

For multinational innovators, the implications are clear. Engagement in India now extends beyond commercialization. It calls for collaboration in research, investment in digital and scientific ecosystems, alignment with national health priorities and partnership in strengthening health delivery.

India’s Strategic Role in Global Health Innovation

India’s rise in global health innovation reflects the alignment of policy, market growth, digital infrastructure, and scientific capability forces that together are reshaping where and how healthcare innovation occurs.

For multinational companies, India now represents a full-spectrum innovation environment. It is a place to conduct clinical research across diverse populations, scale manufacturing and supply chains, deploy digital health at a national scale, and co-develop solutions addressing both local and global health challenges. Increasingly, India is not simply a recipient of innovation developed elsewhere. It is becoming a co-creator of next-generation health.

This shift changes the strategic equation. Market entry alone is no longer sufficient. Meaningful engagement requires partnership with policymakers, regulators, scientists, health providers, and digital health ecosystems. Organizations that invest in collaboration, align with national health priorities, and contribute to strengthening healthcare systems are most likely to succeed in India’s evolving landscape.

BIOAsia sets the stage for this transformation. It is more than a conference. It is a convergence of global health ambition, scientific capability, and policy momentum. The conversations taking place in Hyderabad mirror a broader reality: the geography of health innovation is expanding, and India is now central to its future.

For global health innovators, the question is no longer whether India matters. The question is how deeply they choose to engage in shaping what comes next.

The post India: The Growing Focal Point for Health Innovation appeared first on Medika Life.

I have spent more than 30 years in healthcare with one consistent mission: helping people sustain and improve their lives. That mission has guided my work across large pharmaceutical companies, entrepreneurial startups, and academic institutions. It has shaped how I view innovation—not as a luxury, but as a necessity.

We often speak about healthcare innovation as if it exists in a vacuum. It does not. Innovation only matters if patients can access it, understand it, and afford it. Today’s system too often breaks that chain.

The U.S. healthcare system has evolved to prioritize risk management over prevention, short-term cost containment over long-term health, and utilization controls over patient outcomes. The consequences are real. Breakthrough therapies are delayed or denied. Preventive medicines are underused. Patients are left navigating complexity at the very moment they are most vulnerable.

However, innovation has repeatedly proven it can change the trajectory of disease—and lives—when it reaches patients.

Earlier in my career, I had the opportunity to help build Claritin into a household name. What made Claritin transformational was not just the molecule, but access. Non-sedating allergy relief allowed people to function—to work, learn, drive, and live daily life without compromise. We paired scientific innovation with brand-building, education, and emerging digital tools to enable patients to engage with their care in new ways. That experience taught me something enduring: innovation fails when it remains trapped behind complexity.

As digital channels emerged, I saw how virtual access could democratize care. Early online refill capabilities and digital front doors were not about marketing. They were about meeting patients where they were. Innovation is not only what happens in the lab; it is how solutions are delivered in the real world.

More recently, my work in cardiovascular and preventive medicine has reinforced this belief. Cardiovascular disease remains the leading cause of death globally, yet preventive innovation often struggles most to gain access. When therapies reduce future heart attacks, strokes, and hospitalizations—but do not show immediate cost offsets within narrow budget windows—they face resistance. This is actuarial logic colliding with human biology.

But prevention works. Inflammation matters. Long-term risk reduction matters. Helping people avoid catastrophic events enables them to remain productive, engaged, and present in their lives and with their families. The value of that outcome is difficult to capture on a quarterly balance sheet, but it is undeniable.

Innovation also matters because healthcare is not static. Populations are aging. Chronic disease is rising. Demand for care will only increase. Without continued pharmaceutical innovation—new mechanisms, better tolerability, improved adherence—we risk managing decline rather than enabling vitality.

Critics often frame innovation and affordability as opposing forces. They are not. The real tension lies between short-term system incentives and long-term societal benefit. When access to effective therapies is delayed or denied, costs do not disappear. They shift—reappearing as hospitalizations, disability, lost productivity, and diminished quality of life.

I have worked inside large organizations, small startups, and everything in between. I have seen how difficult it is to bring a medicine from concept to patient—and how fragile that final step of access can be. That is why innovation must be paired with thoughtful policy, modernized reimbursement, and a patient-centered view of value.

Healthcare should not be about simply surviving longer. It should be about living better for longer. Medical innovation, particularly in pharmaceuticals, plays a central role in making that possible. Even in a system burdened by complexity and constraints, innovation remains one of our strongest tools for advancing healthcare.

After three decades, my belief has not changed: when science, access, and mission align, lives improve. That is worth fighting to achieve.

The post Medical Innovation Still Matters—Even When the System Makes It Hard appeared first on Medika Life.

CNS Summit: A Community, Not a Conference

The CNS Summit is less an event and more a movement, the roughly 900-person ecosystem of leaders, scientists, entrepreneurs, and communicators is bound by purpose. Through the years, it has become an “industry reunion” for those working at the intersection of science and humanity. Attendees don’t simply show up for “unscripted” presentations or networking; they come to commune, share ideas, listen and support each other’s journey.

Founded and carefully curated by Amir Kalali, MD, a former Quintiles executive, who focuses on the intersection of life science and technology, believes collaboration unleashes humanity’s greatest potential, Summit operates on the belief that innovation in clinical research and drug development depends on curiosity and connection.  Summit cultivates an atmosphere where hierarchy dissolves. CEOs engage with early-career professionals. Startups find champions among seasoned executives. Conversations flow freely, often long after formal sessions end. As the website declares, “The Summit brings together a curated group of top decision makers from pharma, biotech, CROs, investigator sites, patient advocacy groups, investors and other stakeholders.”

The site also notes a key differentiator for the 2025 gathering: “Networking tables throughout the day. A dedicated space for connection and conversation throughout Summit.” The Summit agenda reinforces that the gathering isn’t just about sessions; it’s about forging connections.

This is the kind of conference where attendees return year after year, sometimes at personal expense, because they recognize that the ROI is more than professional – it’s personal. You leave Boston with new insights, renewed energy and, often, lifelong friends.  What makes CNS Summit unique is that the “price of admission” includes year-long networking gatherings sponsored by Summit community leaders.

“When people introduce themselves at Summit, I want to hear about them — their backstory motivation first, and only then about the problem they are looking to solve,” shares long-time Summit attendee Craig Lipset, DTRA.org Co-Chair, and an advisor to global health innovation enterprises. “This is an event that cherishes long-term relationships between people, which is why this space has become so critical during such a volatile time in the industry,” he adds.

Communication Tip: At CNS Summit, authenticity amplifies influence. Don’t arrive with a set corporate pitch; come ready to share experiences and learn from others. This is a platform for vulnerability, curiosity and conversation, not self-promotion. In a community built on trust, the most powerful communication skill is listening.

The JP Morgan Healthcare Conference: The Ecosystem’s Main Stage

If the CNS Summit is a retreat for reflection, the JP Morgan Healthcare Conference is the watering hole of the life science world, crowded, noisy and absolutely vital. JP Morgan frames it as the “largest and most informative healthcare investment symposium in the industry, which connects global industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community. For one week in January, from January 12^th to 15^th 2026, the health innovation universe converges in San Francisco.

In contrast to the CNS Summit’s intimacy, JPMorgan thrives on scale. It is where biotech, pharma and health system hopefuls present their value proposition to investors, and where global biopharma companies reaffirm strategic direction. From hotel lobbies to sidewalk cafés, every table and hallway becomes a “pitch” space. Deals are initiated, relationships rekindled, and reputations built, rebuilt or crushed. Mega consulting groups such as McKinsey emphasize that this gathering unites “global health and life sciences industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.”

You might attend JPMorgan for 72 hours and never set foot in an official session. Yet those unscripted encounters, coffee chats, quick handshakes, five-minute updates, often shape company trajectories and careers alike for the coming year.

Fern Lazar, Managing Partner and Global Health Practice Lead at FINN Partners, has attended the J.P. Morgan Healthcare Conference since its early days as the original Hambrecht & Quist Healthcare Conference—later acquired by J.P. Morgan. Her advice is straightforward: “Preparation is power. The companies that arrive with clarity, confidence, and proof of momentum leave with stronger reputations, investor trust, and new alliances. Those that don’t are quickly forgotten.”

Communication Tip: At JPMorgan, clarity is currency. In a sea of sound bites, those who communicate with precision rise above the noise. Be concise, compelling, and credible. Articulate what your company does, and why it matters to patients, to systems, and to investors. Every sentence should connect back to the vision and value with plenty of proof points to show you’re on the right track.

Why Both Matter to the Future of Health

Both conferences reveal something fundamental about the health industry’s DNA: innovation depends on both connection and coopetition. CNS Summit reminds us that science is human, built on relationships of trust. JP Morgan reminds us that sustainability requires strategy, clarity and capital.

For communication leaders, the lesson is clear: health innovation demands head, heart and gut.  You must speak to investors in the language of returns and to peers and partners in the language of purpose. The best communicators, like the best leaders, bridge both worlds seamlessly.

The life sciences sector is undergoing constant ebbs and flows: AI, digital biomarkers, decentralized trials and real-world data are reshaping how therapies are discovered, developed and delivered amid this race to raise the bar on all aspects of health access, affordability and delivery, leadership visibility and stakeholder trust matter more than ever.

At the CNS Summit, you cultivate the credibility that comes from empathy and engagement. The Summit community underscores that year-round social element: “Your event registration also provides access to our year-round programming and community activities.”  At JP Morgan, you demonstrate the confidence and messaging that attracts capital and partnership.

One builds influence, the other builds momentum. Taken together, they form a powerful narrative arc for any organization serious about advancing science and health innovation. The leaders who succeed in the next decade won’t just be the ones with great science, they will be those who can translate that science into stories that move payers, policymakers and patients alike. It’s the combination of IQ and EQ that will rally companies toward success.

Final Words: Show Up, Listen, Learn and Lead

Conferences are catalysts for connection.  Their value lies in what happens after the panels end and the flights home begin. Do you follow up? Do you stay in touch? Do you turn introductions into impact?

Whether you’re heading to Boston or San Francisco or both remember: your presence is an investment in the future of your career, company and community. Be intentional. Be visible. Most importantly, be human. In this ecosystem of change, as in medicine itself, the most significant advances begin when people listen, learn and lead together.

The post Two Gatherings, One Mission: Elevating Life Science Leadership and Communication appeared first on Medika Life.

After cardiac surgery, patients are at risk for both high and low blood sugar, which can lead to serious complications. Managing these fluctuations requires careful insulin dosing, but existing protocols often fall short due to the unpredictable nature of ICU care and differences among patients, say the investigators. 

To address this challenge, the research team created a reinforcement learning model, named GLUCOSE, that recommends insulin doses tailored to each patient’s needs. In tests using data from real-world ICU cases, GLUCOSE matched or even outperformed experienced clinicians in keeping blood sugar levels within a safe range—despite having access to only current patient data, while doctors used full patient histories. 

“Our study shows that artificial intelligence can be thoughtfully and responsibly developed to support, rather than replace, the clinical judgment of health care professionals,” says co-senior corresponding author Ankit Sakhuja, MBBS, MS, Associate Professor of Medicine (Data-Driven and Digital Medicine) and a member of the Institute for Critical Care Medicine at the Icahn School of Medicine at Mount Sinai. “In complex and high-pressure environments like the ICU, tools like GLUCOSE can provide real-time data-driven guidance tailored to individual patients. This kind of decision support can enhance safety, reduce the risk of complications, and ultimately allow clinicians to focus more of their attention on critical aspects of patient care.” 

The research team trained GLUCOSE using reinforcement learning, which allowed the system to learn optimal decisions through trial and error. They also used advanced methods—conservative and distributional reinforcement learning—to ensure the model made cautious, reliable recommendations. The model was then rigorously evaluated and compared to real-world clinical practices. 

While the results are promising, the researchers caution that GLUCOSE is not intended to replace doctors. It serves as a clinical decision support tool, offering suggestions that physicians can choose to follow based on their judgment and the broader clinical picture. 

The model could eventually be integrated into electronic health record systems to provide real-time insulin dosing guidance in the ICU, helping reduce complications and improve outcomes. Future steps include adapting the tool for use in other hospital settings, running clinical trials, and exploring ways to integrate it into routine care. 

One current limitation is that the model does not yet factor in nutrition data, which may affect longer-term glucose control. Still, the ability of GLUCOSE to make accurate recommendations based on limited real-time data highlights its potential to enhance safety and efficiency in postsurgical care. 

“Our goal is to develop AI systems that meaningfully augment the capabilities of health care providers and ultimately improve patient outcomes,” says co-senior corresponding author Girish N. Nadkarni, MD, MPH, Chair of the Windreich Department of Artificial Intelligence and Human Health, Director of the Hasso Plattner Institute for Digital Health, and Irene and Dr. Arthur M. Fishberg Professor of Medicine at the Icahn School of Medicine at Mount Sinai, and Chief AI Officer of the Mount Sinai Health System. “By learning from real-world clinical data and delivering personalized recommendations in real time, models like GLUCOSE represent an important advance toward integrating trustworthy data-driven tools into the clinical workflow. This study offers a glimpse of how AI can be thoughtfully embedded into care to support providers in delivering safer, more precise treatment.” 

The paper is titled “A Distributional Reinforcement Learning Model for Optimal Glucose Control After Cardiac Surgery.” 

The study’s authors, as listed in the journal, are Jacob M. Desman, Zhang-Wei Hong, Moein Sabounchi, Ashwin S. Sawant, Jaskirat Gill, Ana C. Costa, Gagan Kumar, Rajeev Sharma, Arpeta Gupta, Paul McCarthy, Veena Nandwani, Doug Powell, Alexandra Carideo, Donnie Goodwin, Sanam Ahmed, Umesh Gidwani, Matthew A. Levin, Robin Varghese, Farzan Filsoufi, Robert Freeman, Avniel Shetreat-Klein, Alexander W. Charney, Ira Hofer, Lili Chan, David Reich, Patricia Kovatch, Roopa Kohli-Seth, Monica Kraft, Pulkit Agrawal, John A. Kellum, Girish N. Nadkarni, and Ankit Sakhuja. 

The study was funded, in part, by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health grant 5K08DK131286, and by the Clinical and Translational Science Awards (CTSA) grant UL1TR004419 from the National Center for Advancing Translational Sciences. Research reported in this publication was also supported by the Office of Research Infrastructure of the National Institutes of Health under award numbers S10OD026880 and S10OD030463.  

See the journal paper for conflicts of interest: https://www.nature.com/articles/s41746-025-01709-9. 

About Mount Sinai’s Windreich Department of AI and Human Health   

Led by Girish N. Nadkarni, MD, MPH—an international authority on the safe, effective, and ethical use of AI in health care—Mount Sinai’s Windreich Department of AI and Human Health is the first of its kind at a U.S. medical school, pioneering transformative advancements at the intersection of artificial intelligence and human health.  

The Department is committed to leveraging AI in a responsible, effective, ethical, and safe manner to transform research, clinical care, education, and operations. By bringing together world-class AI expertise, cutting-edge infrastructure, and unparalleled computational power, the department is advancing breakthroughs in multi-scale, multimodal data integration while streamlining pathways for rapid testing and translation into practice.  

The Department benefits from dynamic collaborations across Mount Sinai, including with the Hasso Plattner Institute for Digital Health at Mount Sinai—a partnership between the Hasso Plattner Institute for Digital Engineering in Potsdam, Germany, and the Mount Sinai Health System—which complements its mission by advancing data-driven approaches to improve patient care and health outcomes.  

At the heart of this innovation is the renowned Icahn School of Medicine at Mount Sinai, which serves as a central hub for learning and collaboration. This unique integration enables dynamic partnerships across institutes, academic departments, hospitals, and outpatient centers, driving progress in disease prevention, improving treatments for complex illnesses, and elevating quality of life on a global scale.  

In 2024, the Department’s innovative NutriScan AI application, developed by the Mount Sinai Health System Clinical Data Science team in partnership with Department faculty, earned Mount Sinai Health System the prestigious Hearst Health Prize. NutriScan is designed to facilitate faster identification and treatment of malnutrition in hospitalized patients. This machine learning tool improves malnutrition diagnosis rates and resource utilization, demonstrating the impactful application of AI in health care.  

For more information on Mount Sinai’s Windreich Department of AI and Human Health, visit: ai.mssm.edu  

The post AI-Driven Model Supports Safer and More Precise Blood Sugar Management After Heart Surgery appeared first on Medika Life.

In this exclusive conversation, I join Hal Wolf, President and CEO of HIMSS, to explore HIMSS’s evolving role in fostering collaboration between hospitals, startups, and policymakers. With the health-ecosystem landscape tracking the early days of a new administration, uncertainties remain—ranging from regulatory shifts to funding allocations. Yet, as Wolf underscores, HIMSS remains steadfast in advancing health equity, supporting digital transformation, and offering actionable strategies that improve care delivery.

This conversation occurs between ViVE in Nashville and HIMSS in Las Vegas—two health gatherings that bring innovators, policymakers, and industry leaders together. While ViVE spotlights digital health startups, investment trends, and edgy sparks, HIMSS serves as the broader convening ground for professionals shaping the future of health information and technology. HIMSS is where the work happens—the “Davos” of health information.

Wolf outlines key issues such as integrating artificial intelligence in hospital systems, the role of primary care in driving better patient outcomes, and how organizations must balance innovation with financial realities. At HIMSS, essential dialogue between established institutions and emerging disruptors has never been more crucial.

Join us as we delve into the forces shaping the health system’s future—where technology, policy, and leadership converge to improve patient outcomes and system-wide efficiency.

Medika Life Editor Gil Bashe: In examining hospital systems, we focus on how information flows within our industry and who has access to it. We still have a lot to learn. These are the first few weeks of the new administration, and we don’t know how things will unfold, how the Senate Committees will approach these discussions, or how actions will be implemented. Will we rely on Executive Orders? If that’s the case, we know where to focus our attention. You’re a remarkable ambassador for the discipline and the sector, and certainly for HIMSS, a professional association, trade association, and global NGO.

People come to HIMSS with tremendous optimism, hoping to gain insights that will make them more effective. I prefer to focus on current developments and HIMSS priorities rather than just reacting to them; that’s a different conversation. I’ll also note that the administration’s conversation around health access, cost, and priorities is still in motion.

HIMSS CEO Hal Wolf: We don’t know enough to discuss new policies and their potential outcomes. One challenge will be securing funding. While we know things will be different, we don’t know where the policies will land. Still, we know that HIMSS is dedicated to its vision and mission statements as they fundamentally relate to realizing the full health potential of every human everywhere.

We are dedicated to health equity and will stay dedicated to it. Our collaboration with governments and NGOs worldwide and our fundamental principles will not change, nor should they! We’ll work with our principles within the context of whatever comes out of the White House.

We worked well with the previous Trump administration and collaborated effectively with ONC and HHS on various initiatives. We look forward to advancing the HIMSS mission within the established parameters.

Bashe: HIMSS is far more than an annual mammoth gathering; it’s a professional society that covers the full spectrum of health information and technology – from cybersecurity to economics to professional development and government policies. Unlike other popular meetings that primarily focus on networking, HIMSS is where professionals from around the globe come to set objectives, strategies, and operational priorities. It’s 30,000 feet and 3,000 in scope.

Wolf: This morning at 6:00 a.m., I had an interesting conversation with the CEO of a successful start-up that is getting distribution now and beginning to roll. At HIMSS, we see the merging of different worlds.

We have our core population, core members of the health ecosystem– hospitals, clinics, health operations, nurse practitioners, CMIOS, CIOS, physician leaders, and administrators. This group represents a significant portion of the HIMSS membership, which includes over 120,000 members.  

On the other hand, we have the entire global app ecosystem that drives innovation and introduces new ideas. As you know, many of these ideas and innovations are driven by personal experiences. A family member encountered a situation, and they tried to solve it. Or have worked in the industry, identified a gap, and pursued it.

They often have a long list of improvements to address, and, often, they aren’t performing well financially. Their reimbursement processes are a little murky, and this uncertainty might increase in 2025.

How much time do they have to integrate innovations that don’t directly impact their outcomes, quality, access or bottom line? Because everything’s being looked at in that piece.

We need to understand that the situation changes as the market evolves. What is the critical point where innovation intersects with standard operating procedures, and what does it look like? How can information from one area influence the other? We must determine how to identify the good and the bad and how to present them to the market.

What happens at the global conference? What happens in chapter meetings? What happens in the papers that are submitted? What happens in the insights? Much of this depends on how these elements connect.

Bashe: Many diverse health information communities come together yearly at HIMSS. You have consistently made this gathering relevant. This year, a new startup section called Emerge addresses a critical need within the HIMSS community. You just started with the story about a startup enterprise. Could you share some important and innovative aspects that will be highlighted at this year’s gathering?

Wolf: That’s a pressing question, so I’ll divide it into multiple parts because it’s challenging.

We’re part of the industry, so let’s return to your original premises to find the answer. You mentioned “competing,” which refers to people competing against each other. However, you also have specific points of interest to consider.

The benefit engine can determine how much money you’ll receive in reimbursement for a particular service. However, if you’re on the insurance or payer side, the configuration may depend on whether it’s for North America or a Ministry of Health. Here, the goal is to anticipate the costs incurred in treating a patient. This perspective aligns with an actuarial professional trying to understand and guide the process forward.

I’ve observed hospital systems are starting to integrate AI functionalities, but currently, only 5 to 7% are using it effectively, from an operational standpoint,

For example, when someone walks to the front desk and says their right arm is hurting, the staff collects the information by typing it into a form. They ask a couple of questions, such as “Who’s your primary care doctor? Who’s your insurance company? Are you on managed care? Is this new? What other ailments do you have? What other prescriptions do you have?” They must ask those questions if they don’t have that information readily available. That data feeds into new algorithms on the AI side.

In the background, AI analyzes the information and makes predictive models about how long this person would be in the hospital, what resources they will consume, and how much revenue it will generate. It’s occurring in the background, without the front desk staff being aware of AI’s calculations; meanwhile, the administrator is beginning to recognize the impact of these advancements. The inbound process begins with appropriate testing, questioning, and, if necessary, into a bed.

Meanwhile, the hospital administrator or the system managing the situation assesses the resources the patient will need, whether they will need a specialist and whether the specialist will be available when needed. By the time an exam takes place, they can inform the patient about what to expect in the next 24 to 48 hours, whether they will be staying at the hospital or going home. This preparation and communication represent the positive aspects of the process.  

The dark side is that the hospital engine in the background might say, “We’re not going to get a lot of money out of this. This is not a good use of our beds/time. If we maximize profits, we should send this person on and see what the next person will bring because our algorithm told us that five people would come in with congestive heart failure, and we do make money on that.”

The person writing this down may never realize what is happening; they won’t know that the system will indicate that the hospital is full, even though there might be capacity. Instead, they will tell the person to go down the street to Acme Community Hospital, which can take care of them, explaining that their system lacks resources. That is a dark coin flip to what could happen.

Bashe: Many hospital networks are acquiring primary care practices as feeder systems in their facilities. For example, if a patient is told, “You need to do a cardiac stress test. Do you have a cardiologist?” and they respond with “No?” the primary care provider can then say, “Why don’t you let me arrange that for you.” The primary care satellite site is closing the loop on a fragmented system. While the hospital system benefits economically from the service, patients benefit, and the primary care satellite site serves as a conduit for care.

I’m always thinking about the benefits of technology in enhancing the hospital and primary care systems. Imagine a doctor saying, “You know, you’ll have many questions. I will be here to help you frame your thinking around those questions. Our system has an LLM model. Let’s call it Dr. Hal. You can ask Dr. Hal every question regarding your congestive heart failure or prostate cancer. Dr. Hal is the composite wisdom of all the experts in our system and is here to address your questions.”

The creative aspect of our discipline, combined with information, is becoming a superpower. We use data to guide our supply chain resourcing and leverage information to promptly provide patients with confidence and comfort. We ensure greater access to accurate information vetted by the system, so patients do not depend solely on Dr. Google.

Wolf: The actual value of AI is knowledge management. It allows a very broad and capable synthesis of vast amounts of data and information that no human can keep up with. For example, in the 1970s, clinicians had access to three to four journals, where editors picked what was important enough to be published. These journals had to be printed and mailed out, resulting in about 400 peer-reviewed articles per year reaching healthcare professionals. If you read one a day, you could keep up. Today, more than 10,000 articles will be published this year alone. All that information, knowledge management, and sharing will occur collaboratively, and there is no way for anyone to synthesize all that.

AI plays a crucial role in operational and clinical decision support by turning information into knowledge, with recommendations that lead to changes in operations, suggestions, and care.

In clinical care, pharmacy, or whatever path you’re on, these recommendations are communicated back to physicians with an explanation of why they are a recommendation and the source of that information.

I think part of the maturity that we’re seeing, and you’ll see at HIMSS 2025, is the evolution of AI since our session three years ago. Back then, we held a session titled, “What is AI, and what does it mean?” The panel discussed its potential application in healthcare, and at that time, chat had just been introduced, and people were starting to look at it. Some people were on stage calling for a six-month hiatus before we allowed anything to go forward.

Last year, we saw glimpses of initial uses of AI being deployed operationally, albeit only in a few hospital systems. But it was beginning to happen, and we knew that AI was in the background of devices or operational considerations. Where would the benefit engines come from? The algorithms were starting to be built, and we had a particular point of looking out for biases. We started talking about biases within AI and realized that no matter what you do, there will always be some biases. It’s unavoidable. What was the source information for AI, and how do I ensure I utilize it to the best of my ability?

You’ll see the presentation of how people are using it on a scale. What are examples of its success, and what are some of its limitations? Numerous applications are set to emerge. You’re going to see them on the floor, where people are using components of AI in the background to produce better products that are more efficient and can guide operations as well as at-home care, and all those pieces are being brought forward. The common link between it and your point is on the information side of the house. How good is the starting information, and how broad does it go? Where is the opportunity from a linking standpoint?

To achieve this, a private-public partnership is essential. If you’re looking at algorithms and information that utilize global data that gets turned into global information, it has an impact. Most healthcare systems around the globe are publicly held. They’re not privately held. The United States is an aberration due to its vast amounts of privately held institutions versus publicly held ones.

Bashe:  Are you seeing more of that regarding the technology being used proactively?

Wolf: Yes, and that’s a good thing. We’ve always wanted to see that proper reimbursement takes place and proper services rendered. Many things in a system can get missed, but not an overwhelming amount.  If hospital systems perform well, they typically operate on a 2 percent to three percent margin, but many run at a loss, making proper reimbursements difficult. Large actuarial departments played a key role in the past, with various organizations providing revenue support, which was a huge thing even 15 years ago. However, over time, those efforts began to converge.

The real opportunity lies beneath the surface. It must coincide with an understanding of the care that was delivered. Right next to that benefit realization is the value proposition. What was the quality of what was rendered? Was the care appropriately given? Did we miss something in the diagnosis?

Bashe: One of the things that I worry about is not New York City or Los Angeles. Medical centers such as Mount Sinai, NYU Langone, Weil-Cornell, Columbia Presbyterian, and Memorial Sloan Kettering, much like their counterparts in Boston, Chicago, and the Bay area, provide excellent care. However, in rural America, someone can live three hours from a tertiary care center.

Your approach of using information to improve the care of almost 29 percent of the US population applies, I think, to other nations where people live far from centers of excellence. What are your thoughts about devices, wearables, remote patient monitoring and information, and protecting the information from your standpoint?

Wolf:  Wearables and home monitoring have transformed patient engagement, making health data more immediate and actionable. It’s fascinating. My wife and I compare our Oura daily. How did you sleep? How’s your heart rhythm? We’re finding the features and working through them. She lives anonymously. We are very engaged in our health. How far did we walk? What was our heart rate? Let’s do the 6-minute walk today and see. Were you snoring last night?

All of that is going on, and that’s an engagement level. The information flows from me to my ring, and then my ring says, do you want to share it with Apple? I said yes, and my wife said no; she didn’t want it to flow to another company. Apple will know how well I sleep – I don’t worry about it. If they want to dive into it, there is a profile about me and my general health. They could also derive that from the stuff I buy and the credit card information. That’s always been the case.

If you remember, back in the 1980s, we were already using demographic data with Donnelly overlays. I worked for Time Warner in the early 1990s when Time magazines were delivered to your door. The Time magazine that arrived at your next-door neighbor was different from yours—not the content, but the cover and the ads in the back. You may have gotten an ad for a sports car, and your neighbor may have gotten one for a minivan.

It was specifically designed based on the Donnelly reports, which provided insights about the household. We’re starting to shape recommendations at the personal level of the care an individual should receive.

Why wouldn’t a physician or a clinician want every piece of information on this Oura ring to be included in a patient’s profile? This information would help complete the picture needed to utilize sophisticated knowledge management systems, tapping into tens of thousands of research papers and combining that data with the person’s unique health details. The richer that information becomes, the more accurate it becomes, the more mistakes it makes, the more positively it helps the next person.

Bashe: Often, when I speak to doctors and nurses in the health system, we talk about the Electronic Medical Record (EMR). They’re candid: “We have an EMR system—it’s not perfect, we know that, and it’s getting better and better.” Yet, they often say, “Did you read that patient’s EMR data?” and then they’ll say, “I don’t have time to read the EMR.” While best practices come from committees, you play a unique role as an advisor to corporations. You’re the sounding board for major corporations, whether AWS, Epic, Microsoft, or Oracle. I’m sure they will listen to you because you’re the voice of the global community.

Wolf: We don’t have a dog in the race against them as a competitor.

Bashe: As a not-for-profit society that operates at a global NGO level, when you look at your role and the challenges you face, how does HIMSS address constant sector transformation? HIMSS and its members are constantly evolving because you represent applied information. The system is getting more interesting and more creative.

Look at the challenges that HIMSS owns and represents and your mission, which is obviously to improve access to care. As the organization’s leader, you’re clear and committed to this role, but you’ve seen difficulties implementing cultural or systemic changes.

What’s your guidance for the community? Please don’t take out a ruler and slap people on their hands. You’re obviously about supporting the system’s evolution, making it better. Can you share insights on how you’re filtering down best practices within this evolving landscape? How do you reflect on these challenges that arise and guide systems to understand that care is delivered to the front lines and is not always in hospitals? It’s specialists or primary care—physicians in their little offices worldwide.

Wolf: This is precisely what we discuss daily at HIMSS, and it’s central to our global work. Let’s walk through our view of the ecosystem and how we influence what you just related to because it’s our core.

Hospital systems – or, more importantly, governments worldwide – including our own, recognize their fundamental responsibility to care for their populations. Let’s set the United States aside for a second.

Ministries of Health in countries around the world are accountable for the well-being of their citizens. We’ll talk about citizens for a minute. The people living within their country want a healthy population, which improves the economy. They’re smart enough to know that a healthier population, or one cared for, efficiently reduces the constant increase in costs within healthcare systems. No one is looking to save money; instead, the goal is to slow the escalating costs of healthcare systems, which seem to rise every year.  

Information is the driver behind everything, but to your point, the combination of people, processes, and technology shapes the outcome. Technology is rarely an issue here; the challenge lies in implementing and changing culture. The pandemic forced a significant global cultural change, and while it may seem that it’s deeply in our rear-view mirror, its impact is still felt. Telemedicine, the idea of using information, and the idea of remote care to alleviate the pressures on the front line became a standard feature, and people recognize that.

We see the impact in our relationships with organizations like the WHO in Europe. Take Romania, for example, where we just signed an agreement to help them develop a strategic plan to deliver digital health transformation. HIMSS is focused on four major points.

1. First is digital health transformation.
2. Second is the deployment and utilization of AI as a tool.
3. Third is cyber security to protect that information and ensure that it works for the betterment of their ecosystem with less hassle.
4. Fourth is workforce development, which trains people to understand these tools before they can utilize them to their fullest extent.

Those are our four main areas. When we think about digital health transformation, we start with the HIMSS maturity models from five to seven years ago.

Back then, our maturity models were a checklist of technology. Do you have that technology? Are you wired? That used to be the baseline, what we now consider table stakes. It’s not table stakes anymore.

We’ve transformed our maturity models to reflect quality, access, correctness, and fundamental value. How are you using the information? How does it improve the flow?

From an IT standpoint, we began looking at our maturity models like a stack. It starts with the information layer. What does the infrastructure look like? How is it laid out? How does your data need to be laid out? Where does the electronic medical record go on top of that? How do those two pieces feed into each other? How do you utilize the radiology and the pictures that are in there? How does that flow? What’s your analytical layer? How does this work?

Where are you getting your information, and how are you handling your analytics? How does that tie itself back into the infrastructure? How does that information flow from your reporting back into your EMR and the data layer? How does that data layer tie in when discussing the imaging ecosystem? What’s your continuity of care, the CCMM? How does it flow across the board to ensure you’re not dropping a patient?

We’ve created a stack of maturity models that form the foundation of how information flows from the patient across hospitals, clinics, and homes, wherever the case is provided, to ensure you can keep up with them. And we present these maturity models not just as a technology checklist. Anyone can do that—it’s not meaningless—but anyone can do that. The true focus is on how you use these technologies.

How do you ensure that the relationship between the patient and pharmacy utilization, as well as the benefit realization, is maintained? And how does all this tie together?

Whether it’s community service, a hospital system, or a home, what we’ve created in those stacks is a blueprint that any hospital system, country, or large-scale region can use to identify the technology needed and deploy it for its maximum benefit. 

People do assessments in hospital systems. For HIMSS members in the United States, these assessments are part of the membership, allowing them unlimited access to evaluate their systems. They can conduct these assessments online, check their status, and aim for levels 6 and 7, which is when all those benefits kick in. That’s when we do our validations.

We also do white papers, thought leadership, and HIMSS events, panels and educational programs. More than 300 academic programs are coming up at HIMSS in 2025, with more than 150 offering CE credits.

But these experiences are all based on the output, what worked, and what didn’t work. As you know, learning from others’ mistakes is just as valuable as learning from their successes. Some of the most impactful lessons come from those who try something, fail, and then fix it.

That’s where HIMSS and advisory services come in. We’re presenting the aggregated global knowledge of what’s working and what isn’t.

Most ecosystems don’t work the same way the United States does because most don’t have the same amount of money invested in it. We draw from many healthcare systems- from the U.S., to Romania, Italy, Germany, Singapore, Indonesia, Malaysia and Australia. We learn from all these countries, bring it together in our membership, and figure out what we have learned. How does it impact the models? We do these reviews in a constant session. That’s how we make the society work.

Bashe: It’s a brilliant use of human capital and composite wisdom. As we’re gearing toward the end of our conversation, I wanted to ask you about the Emerge Innovation Experience– this is a first-time gathering, but the concept of start-ups at HIMSS is nothing new. What’s different now is that you’ve recognized that start-ups are a unique culture with unique needs. You’ve assembled a cohort of leaders dedicated to helping these start-ups succeed. What are your expectations from Emerge?

Wolf: First, I’m very interested in the outcome of Emerge. This is the first time that we’re going to try to bring that mesh point I mentioned earlier, where innovations meet operations. They’ve chosen some excellent examples of what can come forward. I think it’s got the right practicality and innovative forethought. From what I’ve heard from people involved in it and talking to people on the committee, I’ve listened to everything from “Wow! This is fantastic and very innovative!” to “It could have been stronger.”

If I talk to heavy innovator startups, they reply that it doesn’t go far enough and could be really “wow.” Meanwhile, those focused on operations often reply that it’s “really pushing the edge.” What that tells me is that it’s in the right mesh point.

What I’m curious to see is how it is received. Many smart people have been working on it, focusing on what will have the biggest impact on operations and be ready for prime time tomorrow, especially in areas like AI utilization and operational impact. What is one step beyond? We also have an incubator ecosystem there.

The Emerge Innovation Experience will be unique, and I look forward to that outcome.

Bashe: I always value your candor.

Wolf: Sometimes, I can get criticized for it, but I believe in absolute transparency. The beautiful part about thought leadership is that we share these thoughts, which makes HIMSS thrive. Transparency is a strength in a positive society. If we’re not transparent with each other, we can’t advance. My grandfather taught me a long time ago that the three most essential phrases in business are “I don’t know, I’ll find out, and I’ll get back to you.” “I don’t know” is critically important.

What’s beautiful about healthcare is that you learn something new every day. It’s impossible to be in the health sector without learning something new every day unless you don’t ask a single question, read nothing, or stay in a room and shut the door.  

Just today, I learned something about HIMSS. I didn’t know because I was asking about a process. A question was raised, and I followed the thread through the organization and found one I’d never seen before, which was exciting.

I appreciate the philosophical and real questions you’re asking. We’re excited about HIMSS 2025 and the learning opportunities it will offer. It’s also about the big picture of what’s happening globally. We call it the Global Conference because it brings together Ministries of Health and NGOs worldwide. It all comes together. This is our largest membership meeting, and we’re thrilled that there’s at least a 35% increase in people signing up for HIMSS membership compared to last year.

Bashe: I’ll be attending this year. As always, thank you for the in-depth exchange. *****

In this insightful conversation, Hal Wolf, President and CEO of HIMSS, explores the critical forces shaping the sector’s future. As industry and governments navigate a rapidly evolving policy landscape under a new administration’s eyes, hospital systems, startups and policymakers must adapt to changing regulations, funding challenges, and digital transformation. Wolf highlights HIMSS’ role as a global leader in uniting a diverse ecosystem to advance health equity, interoperability, and patient-centered care.

A key theme of the discussion is how data and AI are transforming payer, provider and product innovation operations – how information can improve people’s lives. Wolf explains how AI-driven predictive models are integrated to optimize patient care and resource allocation. However, he also warns of ethical concerns—such as the potential for financial-driven decision-making that could prioritize revenue over patient needs. HIMSS plays a vital role in ensuring there is a balance between digital health innovation aligns with quality care and equitable access.

As digital tools, AI, and large language models (LLMs) become more integrated into healthcare, Wolf and Bashe discuss how these advancements can empower providers and patient-enhancing decision-making, improving operational efficiency and offering trusted, system-vetted health information.

As HIMSS prepares for its annual global conference, Wolf emphasizes its role in shaping industry priorities. HIMSS is not just an event; it’s a society that defines strategies, policies, and innovations that drive the future of health. With an expanding ecosystem of startups and industry veterans, HIMSS remains a pivotal force in bridging technology, policy and patient care.

The post The Future of Health Information and Innovation: A Conversation with HIMSS CEO Hal Wolf appeared first on Medika Life.

Perhaps the biggest wild card is Donald J. Trump’s return to the White House and the nomination of several candidates who have suggested that they will reinvent Health and Human Services, the Food and Drug Administration, Centers for Disease Control, and the Centers for Medicare and Medicaid Services—key agencies that set the agenda for public health and innovation.

The second unknown is the thin line separating misinformation from disinformation.  Historically, we looked to public health scientists to guide us.  Now, we are uncertain who to trust regarding health information.  Advice:  Do not rely on “X” as a fact-checking source – it’s merely noise.  But can you trust significant news sources, C-Suite execs, or elected officials?  It’s hard to say.  There is a vast divide between an honest mistake and willful deception. When it comes to health, do your homework – always!

A third factor must be included in the many 2024 health rankings and “Top 10” analyses that will appear in the days ahead. Our planet’s and people’s health are deeply intertwined. Rising temperatures, air pollution, and extreme weather events are not just environmental concerns but public health emergencies. These factors disproportionately impact vulnerable populations, exacerbating chronic conditions like asthma, cardiovascular disease, and mental health disorders. Addressing these challenges requires health professionals to embrace a broader perspective, recognizing that the fight for cleaner air, sustainable food systems, and resilient communities is inseparable from the mission to improve individual health outcomes.

Here are 10 health-sector developments—not ranked—to watch in the coming year, determined by media coverage, reader interest, and personal interest. These “10” could be Top Hundreds or Thousands. Happily, there were many advancements in 2024 to applaud. Yet, the pain points, too, are many. There are many publication lists to check – reviewing many is worthwhile. What is most important is to reflect on the needs of people and planet and commit to make a difference. The planet doesn’t need people. People need the planet. Equally so, people need each other.

This list’s topics were selected using data from global news outlets, academic publications, press releases, analytics platforms like Google Trends, and social media engagement metrics. While the list reflects the broad measure of public interest, it provides an overview of some of the positive and most worrisome health shifts and signals of what lies ahead.

1. AI-Powered Diagnostics Revolutionize Early Detection

Augmented implementation (AKA artificial intelligence) will redefine diagnostics in the years ahead. AI is poised to redefine diagnostics, with breakthroughs in the early detection of diseases like pancreatic cancer offering unprecedented accuracy and saving lives. Recent breakthroughs set the stage for broader adoption of AI in detecting other cancers and chronic diseases in 2025 and beyond, enticing the biopharma sector to interest in clinical trials to develop treatments for these deadly cancers.  This is a prime example of where AI can become a tipping point for earlier interventions and better patient outcomes globally.

2. India Leadership in Affordable Vaccine Development

India is quietly solidifying a reputation as the “pharmacy of the world” through several initiatives, such as launching a low-cost universal flu vaccine. Developed through a groundbreaking public-private partnership, this vaccine leverages advanced mRNA technology to provide broad-spectrum protection against multiple flu strains. By prioritizing affordability and accessibility, the initiative aims to protect millions of people in low- and middle-income countries, showcasing a scalable model for addressing global health inequities.

India has all the pieces to become a more significant player in the life science innovation puzzle – talent, scientific rigor, and an open-minded government willing to align its drug regulatory system with the world’s gold standard – the Food and Drug Administration.

India’s new rare disease center in New Delhi addresses critical global health gaps, setting a precedent for similar initiatives worldwide. Keep an eye on future developments from India to the world and investments from US-based life science companies in India’s strong talent base.

3. Breakthroughs in Alzheimer’s Disease Treatment

A novel gene-editing therapy targeting the APOE4 gene variant in the United States shows promise in addressing Alzheimer’s progression, and three new drugs were approved in the United Kingdom that may slow down memory decline in early Alzheimer’s disease. This continuing commitment by life science companies to invest in Alzheimer’s treatments after waves of disappointments could mark a turning point in one of the most vexing and worrisome neurodegenerative diseases.

Additionally, long-standing preventive disease pioneer Dean Ornish, MD, Founder and President of the Preventative Medicine Research Institute, has shown a possible pathway to reversing Alzheimer’s symptoms without medication. Ornish’s research on lifestyle interventions—emphasizing diet, exercise, and stress management—gained significant attention in 2024 and highlights the role of holistic approaches in improving cognitive health. His pathway does not dismiss using prescription medicine. Leading medical minds and consumers’ minds should take lifestyle medicine seriously.  It’s not the first time that Dr. Ornish has been proven right.

4. United Kingdom Moves Toward Digital Health Leadership

The United Kingdom launched a nationwide digital health initiative integrating wearable technology with its revered National Health Service (NHS). By enabling people to track chronic conditions like diabetes and hypertension in real-time, the initiative enhances patient engagement and accelerates preventive care delivery. Early results indicate improved patient outcomes and reduced hospital admissions. Looking ahead, 2025 could see the expansion of this initiative to include predictive analytics, further enhancing preventative care and patient empowerment.

UK Finance Minister/Chancellor Rachel Reeves announced in 2024 that the government is increasing the national health budget by US$29.33bn, a significant increase in NHS resourcing. Increased investment in infrastructure, technology and patient care position the United Kingdom as a launching point for new biomedical research and innovation waves.

5. Cancer Vaccines Gain Momentum

Personalized cancer vaccines emerged as a game-changing innovation in oncology. These vaccines train the immune system to target and destroy cancer cells based on the unique genetic mutations in an individual’s tumor, offering a highly tailored approach to treatment. A U.S.-based biotech company reported successful Phase 3 trial results for a melanoma vaccine, demonstrating significant reductions in recurrence rates.  

One promising example is the Moderna and Merck mRNA-based vaccine program for adjuvant treatment of high-risk melanoma. In Phase IIb results, the therapy showed a 44 percent lower risk of cancer recurrence or death compared to Merck blockbuster cancer drug Keytruda alone. Ongoing trials are exploring its efficacy in combating other cancers, such as lung and breast cancer. These are rigorous clinical programs with all the scientific peer-review requirements of a new medication.

6. America Begins to Take Serious Note of Obesity

The United States has finally begun to address obesity as a serious health concern. New policies and initiatives have been implemented to combat this epidemic, including improved access to nutrition education, increased funding for obesity research, and the development of innovative treatment options. Food and Drug Administration approval of new weight-loss GLP-1 drugs has sparked hope for more effective interventions. Additionally, public health campaigns have raised awareness about the long-term health risks associated with obesity, leading to a shift in societal attitudes and increased support for those struggling with weight management.

While weight-loss drugs offer promise, addressing obesity as a multifaceted health issue—spanning diabetes, heart disease, and more—remains critical. However, medications alone are not the miracle solution to the world’s weight problem. Will 2025 become the year of recognizing obesity as an umbrella disease?

7. Israeli Innovation –  Resilience Under Pressure

Sudden attacks from all directions would consume any nation’s emotional and physical energies. If so, the past 16 months should absolutely distract Israel – a country the size of New Jersey – and its nine million Jewish, Muslim, and Druze citizens – from anything other than self-defense.  Despite incredible challenges, Israel continues to innovate, with its 1,600 life science companies driving advancements in digital health, diagnostics, and bio-convergence. Israeli startups raised $2.43 billion in the third quarter of 2024 across 99 rounds, representing a 32 percent increase compared to the same period in 2023 (pre-October 2023)

The number of groundbreaking Israeli-developed medical devices, biologics, and information technologies incorporated into US-headquartered life science companies’ pipelines and product portfolios secures this nation’s position as a global innovator hub. Its role model hospital, Sheba Medical Center, ranks among the world’s top health systems and seamlessly integrates the country’s cutting-edge technologies in intensive care, telemedicine, early diagnostics, smart surgical equipment, and digital imaging throughout its system.

Israel is taking another leap in health innovation through its investment in bio-convergence. It is poised to play a significant role in the next technological wave of the 21st century. 

8. US Advances in Regenerative Medicine

Regenerative medicine focuses on repairing or replacing damaged tissues and organs, tapping into the body’s natural healing processes. Innovations like stem cell regeneration, cell therapy, diabetes and regenerative knee treatments offer alternatives to invasive surgeries and improve outcomes for chronic conditions.

Regulatory frameworks are crucial to this progress, providing clear guidelines and streamlined approval processes to ensure safety while fostering innovation. As regenerative medicine reshapes health delivery, it stands out as a transformative force in addressing some of the most pressing medical challenges. It is science fiction in many ways—maintain an open mind.

9. Global Antimicrobial Resistance Collaboration

The WHO’s global antimicrobial resistance network is a critical step in combating superbugs. It enables real-time data sharing to identify resistance patterns and drive new antibiotic development. It is a big deal. In a world where pathogens know no borders, collective action through such a network is essential to safeguarding the efficacy of treatments and protecting lives worldwide. The urgency has willing partners ready to engage.

This collaborative surveillance network is a big step forward in the response to a silent pandemic threatening global health. Coordinated action across nations equips health systems with real-time tools to identify and respond to resistance patterns. The rise of drug-resistant infections undermines decades of medical progress, turning treatable conditions into life-threatening challenges. A unified surveillance network enhances early detection and targeted interventions and drives the development of new antibiotics and stewardship programs.  Watch what happens in the coming year – our well-being is at stake.

10. A New White House Administration – Anxiety Versus Reality

As the second Trump administration prepares to take up residence in the White House, health ecosystem stakeholders are abuzz about potential policy shifts. Drawing from past actions and election campaign rhetoric, it’s anticipated that this administration – based on executive nominees such as Robert F. Kennedy, Jr., might implement changes through executive authority, bypassing congressional approval.  Food regulation policy is almost a given.  What about access to (some) vaccines? How about the review and regulations of medicines?  Verbal controversy leaves many wondering what will happen next.

The incoming administration’s health policy agenda remains uncertain, with potential changes to the ACA, Medicaid, and reproductive health policies sparking debate. Additionally, there may be moves to restrict access to abortion and contraception, reshape Medicaid through waivers and work requirements, and revise policies affecting LGBTQ+ health and immigration-related health needs.  The possibilities that can generate anxiety are numerous.  Wait and watch!

The Year Ahead and Beyond

These 10 health developments reflect the intersection of innovation, policy, and global collaboration. As we navigate 2025, the focus on improving lives and addressing disparities remains our collective responsibility – to rally to ideas and innovations that can improve people’s and our planet’s well-being.

From AI-supported diagnosis to vaccine breakthroughs in India and digital health leadership in the UK, the global health community demonstrates endless ingenuity. The developments of 2024 offer a roadmap for the future, proving that innovation is a team sport and together can overcome even the most formidable health challenges.

But innovation is like a Jenga structure—pull out the wrong piece at the wrong time, and health innovation can crumble or come to a screeching halt. It rests on three pillars: 1. People, 2. Policy, and 3. Investment. If policies do not support continued biomedical advances, equity and big business will likely search for other sectors that offer promise with a clear vision of a return on investment.

Let’s watch and advocate for a world where health in developed and emerging nations remains a top priority.

The post 2024 Health Trends: Progress, Challenges, and Opportunities appeared first on Medika Life.

For too long, “AI” has been the abbreviation for “artificial intelligence.”  Reject that label!  It’s not only limiting – it’s incorrect.  The information gathered and parsed comes from real-world sources – patients, payers, product innovators, policymakers, and providers.  It is composite data, once called “big data,” sliced and diced through machine learning and then applied to good, sometimes life-sustaining use.  It’s time we acknowledge how “AI” has become a practical source for talent and organizational enhancement.

Health Enters the Age of “Augmented Implementation”

Here’s a dive into 10 transformative examples of how “AI” enables people to tap into their significant potential to heal and accelerate care delivery.  Change is always hard, even when the advantages appear evident, as it requires revamping processes and policies.  However, as innovation theorist, AI philosopher and Nosta Lab Founder John Nosta reflects: “Culture crushes innovation.” 

Nosta shares with Medika Life readers: “AI, particularly through large language models (LLMs), is revolutionizing healthcare by fostering ‘learner-centricity.’ This approach places physicians, patients, and healthcare systems at the center of a dynamic, personalized learning process. LLMs provide tailored, context-specific knowledge, enabling real-time insights and deeper understanding. Whether it’s a clinician refining diagnostic skills or a patient comprehending treatment options, LLMs create a collaborative learning ecosystem. This synergy enhances the healthcare experience, empowering all participants through shared knowledge and continuous growth.”

The culture of medicine is storied and slow-moving. Still, these 10 approaches to weaving AI into the health system are piquing people’s priorities and enthusiasm for greater use. The wave of universal acceptance is underway.

1. Revolutionizing Patient-Clinician Interaction

Ambient Listening Technologies (ALTs) are modernizing how clinicians transcribe medical documents – by capturing, recording, managing, and analyzing audio data from the patient exam room. AI transcription tools like the Nuance Dragon Ambient eXperience (DAX) from Microsoft streamline recording tasks that once consumed chunks of a clinician’s day. AI-driven transcription systems record and summarize patient-clinician conversations, enabling providers to focus on patients rather than documentation. The plus for doctors is reduced admin time; for patients, it provides the benefit of ensuring their provider has real-time notes for follow-up care delivery.

2. AI-Enhanced Diagnostics are Challenging the Future of Illness

Technologies like DeepMind AlphaFold provide unprecedented insights into protein structure prediction, accelerating drug discovery and enhancing diagnostic tools for diseases like Alzheimer’s and certain cancers. Anyone tracking the field of AI-empowered diagnostics would do well to keep a close eye on innovation in this space.  The 2024 Chemistry Nobel Prize was awarded to John Jumper, PhD, and Demis Hassabis, PhD, at Google DeepMind in London for developing this game-changing AI tool for predicting protein structures.  The Galien Foundation Prix Galien is often called the Nobel Prize of the Life Science industry.  Viz.ai, a pioneer in AI-powered disease detection and intelligent care coordination, received the 2024 Prix Galien USA Award for its Viz HCM™ (Hypertrophic Cardiomyopathy) module.  Keep an eye on these companies and their advances.

Rob Havasy, HIMSS Senior Director of Informatics Strategy, representing one of the most influence professional communities – the leaders from health institutions and governments worldwide – offered this exclusive comment to Medika Life:

“AI has been part of many radiology workflows for years, but data from our HIMSS Market Insights surveys show one of the fastest growing applications right now is ambient AI and other AI tools to relieve some of clinicians’ documentation burden. These tools either help clinicians capture information from a visit or streamline patient-provider communications by creating discharge instructions or helping to manage overflowing inboxes.”

3. Accelerating Drug Discovery and Clinical Trials

AI is catalyzing innovation in drug development, a process that traditionally spans over a decade. Platforms like Hong Kong-headquartered Insilico Medicine and companies like Exscientia are applying machine learning to design drug molecules faster than ever. Meanwhile, decentralized trials are becoming more accessible through collaborative pathways set by organizations such as the Decentralized Trials & Research Alliance (DTRA), a central gathering point for regulators and industry leaders to shift the conversation from theoretical to operational regarding implementation.

Dr. Amir Kalali and Craig Lipset, pioneers in clinical trial innovation, champion this collaborative model that draws in biopharma-sector leaders, CROs, and FDA and EMA regulators. The DTRA Co-Chairs have long advocated that decentralized clinical trials (DCTs) supported by AI tools broaden access and reduce biases. These collaborations demonstrate how AI unlocks new efficiencies and enables more inclusive participation, particularly among underrepresented populations.

4. Predictive Analytics for Patient Safety

Predictive analytics powered by AI is transforming patient safety in hospitals. For example, Qventus predicts and mitigates perioperative complications. At the same time, companies like Stasis Labs, Current Health, and Vytrac provide real-time in-patient and at-home monitoring, sending vital sign data to nurses and doctors so they know their patient status and triage care.  Amy Abernathy, MD, PhD, has served in several high-profile roles that cut across the health ecosystem, from Principal Deputy Commissioner at the Food and Drug Administration (FDA) and is now Co-Founder of Highlander Health, a bold new organization advancing clinical research and patient care through learning labs, investments, and philanthropy, comments: “AI is transforming how we approach patient safety by intervening in a proactive measure rather than a reactive one.”

5. Addressing Mental Health Needs with AI

Mental health care is becoming more accessible with AI-driven platforms such as Woebot Health and Wysa. These companies are using AI to provide scalable, CBT-based support for conditions like anxiety and depression, often meeting the needs of underserved populations without ready access to mental health services. Another approach led by GrayMatters Health enables mental health professionals to address PTSD through neuromodulation – an FDA-approved for-use approach designed through years of data aggregation.  Noted digital health pioneer, inventor, and  Founder and Curator for NextMed Health, Daniel Kraft, MD, notes: “AI-powered mental health tools are filling the gaps in traditional care delivery, providing immediate, accessible, and empathetic support when people need it most.”

6. Driving Precision Medicine

Precision medicine, enabled by AI, is bringing targeted therapies into sharper focus. Collaborating with Roche, Foundation Medicine uses genomic profiling to guide cancer treatments. Similarly, Tempus leverages AI to connect molecular and clinical data, accelerating therapeutic breakthroughs. The combination of high tech with high science has enabled scientists with support from private equity and academic institutions worldwide to create companies at the vanguard of the discipline in the UK Golden Triangle, Southeast Asia, and the Cambridge/Boston innovation hub. LABIOTECH author Willow Shah-Neville wrote a concise report of 12 biotech unicorns rated in order of their valuations according to CB Insights. It is worth examining how these fast-moving innovators apply information technology to augment their scientific implementation.

7. Streamlining Hospital Operations

AI tools enhance hospital operations, optimize workflows, and improve patient outcomes. For instance, GE Healthcare Command Centers use predictive analytics to manage patient flow. Other companies, such as LeanTaaS, with its iQueue platform, improve operating room and infusion suite scheduling. Hyro is a much-watched hospital workflow optimizer with services that cut across administrative and clinical departments and add AI to Epic workflows, improving access to care. Edward Marx, a global healthcare consultant and former Cleveland Clinic CIO, emphasizes: “Operational AI is reshaping how hospitals function, eliminating inefficiencies and ensuring resources are used where they’re needed most.”

“Top Trends in Healthcare and Life Sciences” Microsoft video episode titled “The power of information to improve healthcare,” Gil Bashe, Chair of Global Health and Purpose at FINN Partners and Medika Life Editor-in-Chief, joins Tom Lawry, formerly National Director for Artificial Intelligence Health and Life Sciences at Microsoft and now Founder of the AI consultancy Second Century, talk about the opportunities and obstacles in health, AI, and the power of information.

8. Promoting Health Equity Through AI

Medtronic AI-enabled remote monitoring devices are helping bridge the care gap in underserved areas. Similarly, PathAI, in collaboration with Quest Diagnostics, is leveraging “machine learning to improve diagnostics in resource-limited settings, ensuring equitable access to healthcare.  Michelle Longmire, MD, a Stanford-trained dermatologist and founder and CEO of Medable, which offers the research-based biopharma industry an array of research tools with a unified platform, adds: “AI’s potential lies in its scalability, which can extend high-quality care to populations previously overlooked by traditional systems.”

9. Harnessing AI for Population Health

AI is transforming public health by integrating social determinants of health into predictive models. Companies like Epic Health Research Network and Innovaccer are helping health systems anticipate and address population health challenges more effectively. Michael Rosenblatt, MD, with his storied career as a scientist and teacher, having served as Chief Medical Officer at Merck and Flagship Pioneering and now as Co-Chair of the Galien Foundation, notes: “AI-driven insights empower health systems to deploy resources strategically, reducing disparities and improving outcomes across entire communities.”

10. Empowering Patients with Wearables and Digital Health Platforms

Wearables like the Apple Watch have popularized health tracking. Still, more specialized solutions, such as AliveCor and Biobeat are examples of advanced monitors delivering medical-grade heart data enabling patients to access, manage, and share their data and connect with their physicians. Additionally, platforms like the Belong.Life Dave AI focuses on cancer care by guiding patients with tailored recommendations, educational content, and peer support.  David E. Albert, MD, Oklahoma native, physician, inventor, and serial entrepreneur, is the founder of AliveCor and a long-time AI champion, says, “AI will play a role in reducing data into manageable and actionable information for clinical decision-making.”

Looking Forward: A Future Shaped by Collaboration

AI progress in health settings during the past five years illustrates what’s possible when technology meets the demands of patient care, equity, and innovation.  

Is “AI” still threatening and misunderstood?  Absolutely! The term “artificial intelligence” is a threatening misrepresentation of the idea that people will become secondary to machines processing vast amounts of data (largely) accurately and in a blink. However, technology is continuously called upon to automate repetitive tasks.  It does not alone transform people’s health or the fractured health ecosystem – instead, it’s the human desire to question, collaborate, and generate shared – augmented – wisdom that is core to implementation.  

“Driving measurable value at scale with AI is less about the right technology and more about the right leadership. Is there a sufficient level of AI understanding at all levels of the organization?  Is your culture change-ready or change-resistant,” reflects Tom Lawry, principal of Second Century.  Is AI part of your HR plan? In the end, AI success cannot be delegated. Leadership is the catalyst for unlocking its true potential. This requires vision, strategic alignment, and a commitment to empowering teams to innovate and execute with purpose.”

As more people dip their toes into the tech waters, comfort levels are increasing rapidly. Remember the 15-year time gap between Apple’s failed Newton and the early iPhones? Once the idea of a smartphone caught on, it became a personal must. According to a Pew Research Center Survey conducted May 19 to Sept. 5, 2023, 90% of US adults say they have a smartphone. Soon, AI will be ubiquitous in most health settings.

Say so long to artificial intelligence. Welcome to the age of Augmented Implementation!

The next five years promise even more significant advances, , a thirst to use information to accelerate decision-making, fueled by curiosity and collaborations across sectors and the drive to improve lives globally.

The post AI is Transforming Health Delivery: A Five-Year Reflection appeared first on Medika Life.

If she does not get medicine on board immediately with symptom onset, days of misery ensue.

Migraine is a debilitating neurological disease that affects over a billion people worldwide, with those assigned female at birth significantly more likely to experience it than men (21 versus 10 percent).

This common condition often hits young people the hardest, leading to missed days at work and school, reduced productivity, increased errors, and presenteeism (being present but not fully functioning due to illness).

Today, I’ll briefly explore a new nasal spray for those suffering from migraines.]

Background

Migraines can knock someone out of commission.

Symptoms such as nausea, pain, and light sensitivity can render it impossible to work or care for family members.

Migraine is the leading cause of disability among women.

Many people suffered migraines, including Julius Caesar, St. Paul, Thomas Jefferson, and Charles Darwin.

My friend is one of many searching for better migraine management options.

First, I cannot resist looking at the historical record.

A Brief History of Migraines

The ancient Egyptians described migraines and nerve pain.

Hippocrates (460–370 BC), the father of medicine, was the first to document migraine scientifically.

“A bright light in the right eye, followed by the onset of severe pain in the head, which eventually extended to the entire area.”

Let’s turn to the breakthrough.

A Nasal Spray for Migraines: Timolol

There are many migraine medications, but they sometimes are not very effective, have high costs, or associated side effects.

Migliazzo and Hagan published the first case series of long-term success in treating acute migraines with timolol eye drops.

Timolol eye drops bypass the digestive process when applied to healthy eyes.

They rapidly travel through the tear ducts to the nasal passages, where absorption by the nasal mucosa rivals the speed of intravenous injection.

A nasal spray makes sense since the mechanism of action is through the nose (and some have trouble using eye drops).

Nasal Spray Study

Researchers had a national compounding pharmacy create a nasal spray device to deliver Timolol.

Patients spray each nostril quickly at the first onset of headache.

If symptoms persist, they can repeat the spar 10 to 15 minutes later, with a maximum number of sprays found in 24 hours.

No one on beta-blocker medicines was offered the spray.

Nasal Spray Results

Here are the results of a small series of 16 patients with refractory migraines:

Ten patients (63 percent) reported being pleased with the nasal Timolol and added it to their preferred treatment.

There were no significant side effects.

My Take

A National Headache Foundation survey indicates that the majority of individuals with migraine are unable to control their disease and are dissatisfied with current preventive treatment options.

We must do better.

The reported series on nasal timolol is remarkably small.

Concerning safety, Timolol has been approved for glaucoma, many cardiovascular conditions, and migraines for over 40 years, and it has a long track record of safety.

If you have acute migraine headaches that are not responding satisfactorily to standard medicines, nasal spray timolol 0.5% may offer you another option.

Finally, the study authors offer this:

“A huge advantage of this treatment is that it is presently available from O’Brien Pharmacy in Kansas City and Bayview Pharmacy in Rhode Island by prescription. The formulation has been published in the International Journal of Pharmacy Compounding, so other local compounding pharmacies should be able to prepare it.”

The study authors indicate they have no financial conflicts.

The post New Hope for Migraine Sufferers: Could a Simple Nasal Spray Be the Answer? appeared first on Medika Life.

Recurrent respiratory papillomatosis (RRP) is just one of those unexpected HPV-driven conditions. RRP is not a sexually transmitted disease and patients are not contagious. An estimated 15,000 to 20,000 people in the United States and more than 125,000 globally have RRP. This burdensome disease takes several forms and impacts people’s upper or lower respiratory tracts or presents as recurrent lesions on the vocal cords or adjacent tissues that require endless corrective surgeries. The treatment often results in permanent damage to a person’s voice.

RRP falls into two demographic subtypes: juvenile-onset (even toddlers) RRP and adult-onset RRP. Each presents unique medical management and lifestyle difficulties, and in addressing these challenges, patient advocacy—raising awareness and building a supportive community—is critically important.

Since it has no Food and Drug Administration (FDA)- approved treatment or cure, patients and scientists devote energy and resources to ensuring people with RRP have access to information. They are in the loop about clinical possibilities for this rare disease. No cure doesn’t mean there is no action!

Beyond the physical challenges of dealing with the disease – and the missed life events and career detours resulting from repeated surgeries, patients also face significant and demoralizing administrative challenges, such as battling payers to cover care using drugs not indicated by the Food and Drug Administration (FDA) for RRP or deemed “not sufficiently proven.”

The lack of treatment does not mean the RRP community is without hope. They are resilient and courageous and are making meaningful connections through the patient advocacy efforts of the Recurrent Respiratory Papillomatosis Foundation. They are reaching and inspiring researchers at the National Institutes of Health to pursue breakthrough research and oversee clinical trials. They also connect with scientists advancing possible therapies at discovery and clinical-stage biopharmaceutical companies like Precigen and encourage them to move forward by enrolling in clinical trials.

Collaboration Accelerates Change

When people unite, their presence creates energy. The Recurrent Respiratory Papillomatosis Foundation, biotech company Precigen, the National Cancer Institute (NCI), and RRP patients and their caregivers met on June 11th at the National Press Club for the Inaugural International Recurrent Respiratory Papillomatosis Awareness Day. This was an inflection point for those who follow the rare disease category.

The gathering wasn’t about hype or baseless optimism; it was a meeting that brought people together, prepared and ready to roll up their sleeves and get to work. It was a day that reaffirmed a commitment to transparency and a truthful assessment of the current situation and path forward.

Virginia Senator Mark Warner, chair of the powerful Senate Intelligence Committee, which oversees cybersecurity efforts that are key to healthcare and innovation data protection, kicked off RRP Awareness Day by expressing his support for people with rare diseases and his desire to help RRP patients find their voice. Senator Warner stated his desire to advance research and innovation and ensure access to care, an expression of determination that reflected his long-standing record on behalf of people seeking treatment options and improved outcomes.   

RRP Foundation President Kim McClellan also spoke as an advocate for the RRP community and as a patient. “We are here to raise awareness about RRP and bring together critical stakeholders in a dialogue on important aspects impacting individuals living with RRP,” she said. “We invite and encourage anyone living with RRP, either as a patient, family member or caregiver, to join us in spreading the word about RRP and participate in clinical trials and advocacy efforts.”

The date of this groundbreaking gathering has special meaning for the RRP community. June 11th (6/11) corresponds to HPV variants 6 and 11 associated with RRP. As the date symbolizes, the gathering united people with the disease, their family members, congressional leaders, and researchers from government agencies and corporate partners in a community united in a common cause.

The opportunity to share and hear multiple perspectives enriched discussions and underscored the importance of taking a comprehensive approach to tackling this condition. Panels of experts and patients sharing personal stories about their journeys gave attendees an unmatched opportunity to delve into the intricacies and impacts of RRP.

Helen Sabzevari, PhD, President and CEO of Precigen, expressed that she and her company were “proud to join forces with the RRP Foundation to establish the first global RRP Awareness Day to bring visibility to the many challenges experienced by RRP patients and to help forge connections among patients, clinicians and government officials.”

A former NCI team leader, Dr. Sabzevari’s commitment to RRP awareness and patient well-being as an animating principle is a model biopharma company C-Suite executives would be wise to emulate. For her and her Precigen colleagues, patients are the focal point of every decision, action, and investment.

RRP Awareness Day was an inspiring platform for discussing struggle, stigma, and science. Lunch was optional, but tissues were required as attendees in the filled-to-capacity room listened to a patient panel on how RRP impacts people and their families. They learned how some individuals living with RRP have needed hundreds of surgeries over the years, beginning when they were toddlers or young children in primary school.

Culture Drives Clinical Performance

Therapeutic innovations are needed to ensure that future generations living with RRP have options reviewed and indicated by the FDA for treating this viral condition.

During the event, a panel of representatives from advocacy and research reflected on how their collaborative approach centering around patients – from the design of clinical trials to allocating resources that have enabled patients to participate in those trials – has been vital in accelerating the R&D process toward identifying and developing viable treatments. The panel included James Gulley, MD., PhD., NIH, Senior Investigator, Center for Immuno-Oncology, Acting Co-Director, National Cancer Institute/Center for Cancer Research; Scott M. Norberg, DO., NIH, Associate Research Physician, Center for Immuno-Oncology; Helen Sabzevari, PhD, CEO, Precigen; and Kim McClellan, President, RRP Foundation.

Dr. Gulley, who is part of the NCI team and has been instrumental in advancing research on RRP and its connection to HPV, emphasized the pressing need for innovative therapies. In his panel comments, Dr. Gulley highlighted the importance of collaborative research efforts to explore potential immunotherapeutic approaches that could offer new hope for patients suffering from this debilitating condition.

No Disagreement – Harmony

Panelists Gulley, Norberg, and Sabzevari applauded the patient community, acknowledging the courage of their readiness to volunteer to participate in clinical trials to speed possible therapeutics forward. It was a reassuring presence and a reminder that public-private collaborations, particularly for rare diseases, do more than spark hope; they spur action. The patient-panel takeaways were: (1) Connect with the RRP Foundation, (2) Support ongoing clinical trial efforts, (3) Prevention through HPV vaccination is key.

While there is still no FDA-approved treatment to manage RRP, this community remains resilient and upbeat, inspiring everyone facing the challenge of rare conditions. The RRP Foundation, Precigen, and NCI are on the same page—science is essential. People living with RRP can remain hopeful that this collaboration will continue until actions result in better options for this patient community.

The post HPV Urban Legends – From Contagion to Symptoms to Risks to Prevention – There Are More Rare Concerns that Deserve Our Attention appeared first on Medika Life.

Ninety Nations Are Expected to be Represented At HIMSS

Among those 90 countries will be Israel, well-known for its outstanding health system, novel engineering acumen and always-on entrepreneurial engine. Israeli startups have been instrumental in developing breakthrough technologies and treatments, from telemedicine to augmented intelligence, precision medicine, and virtual and medical imaging. These innovations continuously improve health within Israel, home to Sheba Medical Center, one of Newsweek’s leading global hospital systems. They are exported globally, contributing to the country’s economy and worldwide standing as a top business development partner.

When the war broke out in early October 2023, Israeli attendees planning to attend the Las Vegas HLTH meeting either rushed home to reunite with family members or canceled plans to travel.  HIMSS24 Orlando will be the reboot after six gut-wrenching months when the Israeli Innovation Las Vegas HLTH Pavilion was largely vacated and war broke out.  These resilient innovators will travel to Orlando for their long-awaited plans to connect with the global health information community.

A Private Equity Firm that Champions its Portfolio Companies Globally

eHealth Ventures Group (eHV), an Israeli-headquartered private equity firm with some $1 billion under management, is planning a special HIMSS delegation of 10 of its portfolio companies – enterprises that range from start-ups to in-market companies rubbing shoulders with some of the world’s most prestigious biopharmaceutical and health system players. Some companies joining eHV Partner Ophir Shahaf focus on improving health system use of information and operations; some apply the practice value of AI and GenAI to functions where sufficient human capital is unavailable; others are pioneering new ways to address pressing medical conditions.  All come to Orlando to meet and exchange ideas with US-based colleagues during HIMSS.

Hear Medika Life Editor Gil Bashe’s exclusive interview with eHealth Venture Partner Ophir Shahaf on Healthcare Now Radio: LISTEN HERE.

From Information to Clinical Innovation Israeli Innovators Head to HIMSS

• Coronary artery disease (CAD) is a progressive condition that often remains asymptomatic for years, leading to delayed diagnosis and treatment. AccuLine has developed an accurate and non-invasive exam for the early detection of CAD to prevent millions of heart attacks. The user-friendly exam includes a four-minute measurement of vital signs, safely replacing traditional ergometry. This approach addresses the limitations of existing tools in terms of accuracy, invasiveness, and cost. The company has demonstrated promising clinical results with high precision and cost-effectiveness, supported by strategic partnerships with industry leaders, including Intratech, Sanolla, NovaSight, Lumenis, and Johnson & Johnson.

“In the fragmented health ecosystem, where patients may encounter barriers to accessing specialized care, the technology bridges this gap by offering a standardized and accessible diagnostic solution for CAD, ensuring equitable access to timely cardiac care regardless of geographic location or setting,” said Moshe Barel, Acculine CEO. Streamlining the diagnostic process and providing immediate results can accelerate time-to-care, enable clinicians to initiate prompt intervention, and improve patient outcomes.”

• Agamon Health is an imaging patient workflow management platform that leverages GenAI to connect providers and patients and coordinate the next steps in care management. By seamlessly coordinating interactions among radiologists, referring providers, nurse navigators, and patients, Agamon facilitates early diagnosis, enhances care quality, and boosts operational efficiency. Its platform accuracy has been honed, drawing from more than 20 million radiology reports, and has demonstrated a 55 percent increase in patient adherence and a 10-time return on investment.

“Care gaps are a common and unfortunate part of the health systems in the US because the system is siloed – from clinical and technical perspectives. In radiology, 20 percent of all radiology reports require some follow-up, and more than 60 percent of those patients don’t circle back, said Steve Linowes, Agamon HealthUS General Manager. This happens for several reasons. In many instances, referring providers aren’t connected to the health system that conducted the original radiology procedure, so there isn’t an easy way to communicate or have them order the follow-up procedure. This impacts more than 80 million patients annually and represents billions of dollars in lost revenue to health systems.”

• Insight Axis introduces a diagnostic tool designed for better management of neuropsychiatric disorders and improved psychiatric diagnosis and treatment. Led by a team of experts in electrophysiology, neuroscience, and mathematics, Insight Axis offers an AI-based platform that assesses treatment responsiveness, predicts medication compatibility, and characterizes disorders based on brain signatures. With no known biomarkers available for psychiatric disorders, Insight Axis provides clinicians with objective data from standard EEG tests integrated into its Quantum Physics and AI-based platform. This innovative system, backed by solid IP, promises to transform the approach to psychiatric care, ensuring more accurate diagnosis and personalized treatment recommendations.

• Thousands of neurosurgeries are performed globally daily. Each requires neuromonitoring coverage, and a specialized neurophysiologist oversees the surgeon to prevent potential nerve injuries. However, there is an insufficient number of these professionals to oversee each surgery, increasing nerve damage and paralysis risks for patients undergoing surgery without surveillance. Nervio created the world’s first autonomous neuromonitoring solution, reducing dependence on these high-demand professionals and potentially making neuromonitoring oversight available in every OR globally.

“Why does this matter to health systems, providers and patients?  A particular worry is post-injury post-spine surgery, a clinical concern now monitored using 30-year-old technology,” reflects Nervio CEO Ariel Weinstein, a long-standing entrepreneurial leader. “To increase physician and patient confidence, Nervio has created an expert-trained AI system that mirrors the vigilance of expert oversight. This technology reduces stress, risk and operating costs.”

• NimBio has developed an AI-based disease management platform to transform the treatment of immune-mediated inflammatory Diseases (IMIDs). With its focus on Inflammatory Bowel Diseases (IBD), NimBio is developing flare-up prevention technology through a 100% non-invasive remote inflammation management platform. This advanced technology, including a wearable sensor and AI-based predictive algorithm, predicts flare-ups before they occur, enabling intervention and treatment. NimBio collaborates with clinical and business partners, including Mayo Clinic and AMGEN, as it collaborates within the medical and therapeutic community to secure a unique place, timing, and perfect IMID treatment.

• Through automated data collection and its ultra-lightweight real-time locating system, QLOG enables hospitals to easily track equipment, medical supplies, and patients. By increasing visibility with its data automation solutions, QLOG helps healthcare organizations reduce costs, control processes, and assets, and improve safety and quality of care. The result is 45 percent better equipment utilization, 65 percent less supply loss and waste, and 90 percent improved compliance and safety. Leading health institutions are already deploying the QLOG in Israel and throughout Europe.

“QLOG looks to improve the way healthcare operates. We are proud to be making an impact, redefining the communication channels between the organization and the workforce, and defining how healthcare is managed,” said Dr. Amit Lehavi, QLOG founder and CEO, in announcing a successful funding round. “Our Healthcare Operations Platform displays remarkable financial impact and quality improvements across Israel and Europe. This has a direct positive influence on patient care by reducing nurse burnout and improved retention.”

• RespirAI Medical has designed an AI-powered wearable platform for long-term, at-home monitoring of chronic respiratory diseases. The device is based on a bio-coupling novel marker – measuring synchronization among breathing and walking, detecting COPD flare-ups before they flare out of control. Beyond COPD management, the platform offers health professionals the potential to identify additional respiratory and cardiac complications early and personalize medication management for these conditions.

“The RespirAI solution can improve clinical outcomes for health professionals managing chronic respiratory diseases,” says CEO Nimrod Bin-Nun. “By facilitating early detection of lung function changes and exacerbations, the RespirAI platform enables proactive intervention, reducing hospitalizations, alleviating symptom severity, and saving patient’s lives. The remote monitoring feature enhances patient convenience and lowers healthcare costs, minimizing the need for in-person visits,” he added.

• Chronic lower back pain (CLBP) impacts millions worldwide. Current care methods often focus on symptomatic relief or invasive procedures, overlooking the root mechanical imbalances contributing to CLBP. This fragmented approach leads to prolonged suffering, high healthcare costs, and limited access to adequate care. Symetrify addresses this gap in care by targeting the neuro-mechanical root cause of CLBP, providing efficient and non-invasive treatment that accelerates time-to-care decisions and improves patient outcomes. Software-based, Symetrify provides therapeutic effects while enhancing treatment capacity and efficiency for providers, focusing on patient engagement, follow-up, and retention.

“The workplace setting faces significant challenges with chronic lower back pain (CLBP), impacting millions. Current care methods often focus on symptomatic relief or invasive procedures, overlooking the root mechanical imbalances contributing to CLBP,” says Dana Chanan, CEO. “This approach leads to unnecessary suffering, high health costs, and reduces access to effective care. Symetrify addresses this gap by targeting the neuro-mechanical root cause of CLBP, providing non-invasive treatment to accelerate time-to-care decisions and improve outcomes.”

• Yonalink provides electronic data collection solutions (EDC) for clinical trial sponsors, hospitals, and contract research organizations, enabling the post-COVID ideal of decentralized clinical trials to become a reality. Its platform integrates data collection from patients’ medical devices, wearables and electronic health records (EHRs). It replaces manual processes to improve trial efficiency and reduce staff burnout—Yonalink pioneers EHR-to-EDC data streaming from a global network of more than 7000 medical centers. By simplifying data capture, management and transfer, Yonalink reduces the burden on clinical trial teams.

“By automating the data collection and management process and enabling remote data monitoring from any electronic health record, Yonalink makes clinical trial access available to any patient, anywhere,” reports Iddo Peleg, Yonalink CEO and Co-founder. “The system eliminates errors caused by manual data transfer, frees time for study staff to focus on more critical tasks, and provides sponsors with real-time data oversight to keep trial timelines on track.”

• The economic impact of migraine-related productivity loss is significant, with indirect costs to the US economy ranging from $22 billion to $78 billion annually due to missed workdays and diminished on-the-job efficiency.  Wizermed is developing a solution for migraine attack prediction before onset. Its AI-based platform, Migraine Predict, utilizes smartwatch technology to detect, predict, and manage migraines effectively. The platform can provide a daily “migraine forecast,” accurately predicting whether the next day will likely be migraine-free or if an attack is imminent. This reduces the anxiety and stress associated with the unpredictability of migraines, gives people a greater sense of control of their migraines, and enables earlier, proactive intervention to minimize the impact of a migraine.

“The capacity to foresee and alleviate the impact of imminent attacks holds significant potential for enhancing the well-being of migraine sufferers, who often feel their condition dominates their lives,” reinforces Wizermed Founder and CEO Guy Attar. “This solution empowers individuals with the means to reclaim control over their quality of life. Furthermore, this solution benefits employers by enhancing workplace productivity, reducing absenteeism, and fostering higher employee satisfaction. Notably, there’s potential to decrease the frequency and intensity of attacks, a critical consideration given the substantial prevalence of migraine sufferers in the population,” he adds.

While conflict prevails, many wonder how this impacts Israel’s innovation engine and access to investment.  According to the Israeli business publication The Israeli Business News – The Globes, “Israeli startups raised $500 million in January 2024, drawing from companies’ press announcements.”  The Globes estimates this figure might be even higher as many Israeli companies keep their investment news under the radar screen.

Overall, global investment in digital health, including health information, is down year-to-year from the exuberant COVID years. That trend is confirmed by Galen Growth, one of the world’s leading market intelligence firms; raising half a billion in month one of 2024, the Israeli health innovation sector shows resilience and strength.  HIMSS is an excellent opportunity to meet with these companies and others from the “Start-Up Nation,” whose ideas and intentions are to improve human health worldwide.

The post HIMSS – Global Meeting Ground for Health Info Innovators to Secure Partnerships and Advance Care appeared first on Medika Life.